FDA approves new treatment for hard-to-treat pancreatic cancer
The U.S. Food and Drug Administration announced Wednesday the approval of a treatment for pancreatic cancer that could usher in a new era in managing one of the deadliest forms of the disease.
The U.S. Food and Drug Administration has approved a groundbreaking treatment for pancreatic cancer called Rasonque, developed by U.S. startup Revolution Medicines. Pancreatic cancer remains one of the deadliest forms of the disease, often resistant to conventional therapies. A clinical trial demonstrated that Rasonque could double the survival time of certain patients compared to standard chemotherapy.
Acting FDA Commissioner Kyle Diamantas hailed the approval as a critical new option for patients facing an extraordinarily challenging cancer. While not a cure, the oral medication, which uses a molecule called daraxonrasib, has generated optimism among oncologists and patient advocacy groups. In clinical trials, half of the patients who received Rasonque survived for more than 13 months, compared to the previous standard, which offered only a fraction of that time.
This result marks the first significant breakthrough against pancreatic cancer in decades. Rasonque's approval also opens the door for potential treatments for other cancers, as the drug targets a protein found in various malignancies.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
